{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:13:07Z","timestamp":1771045987058,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johannes Kepler University Linz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections reduce ocular perfusion in patients with neovascular age-related macular degeneration (nAMD). Faricimab blocks both, VEGF-A and Angiopoietin-2. The study investigated the effects of intravitreal Aflibercept or Faricimab on ocular perfusion in patients with nAMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      36 eyes of 36 Caucasian patients with nAMD were initially enrolled and treated with either Aflibercept (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918) or Faricimab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918). Two patients were excluded after screening failures, resulting in 34 eyes (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917 per group) for analysis. Ocular perfusion was assessed using Laser Speckle Flowgraphy (LSFG) at baseline, and 1 and 4 weeks after the first injection. The main output parameter of LSFG, mean blur rate (MBR), was measured in the optic nerve head (ONH) and macula. MBR, defined by an ellipsoid region of interest (ROI), was calculated for the total ONH area (ONH-MA), major retinal vessels within the ONH (ONH-MV), and the tissue area containing microvasculature (ONH-MT). For macular measurements, a square ROI (150\u2009\u00d7\u2009150 pixels) was placed temporal to the optic disc to measure choriocapillaris perfusion (CHOR) without including main retinal vessels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Faricimab group showed a significant decrease in MV (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006) after one week, while the decrease with Aflibercept was not significant after one week (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.29). After 4 weeks, both groups showed a significant decrease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017, respectively). For MT and CHOR, both groups showed a significant decrease in perfusion, both after one and after 4 weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Faricimab caused a more rapid decrease in retinal perfusion, while choroidal perfusion was equally reduced by Aflibercept and Faricimab. These different responses in the vascular systems seem to indicate a different distribution of Tie2 receptors for Angiopoietin-2. These findings warrant further investigation into the role of Tie2 receptors in the vascular response to anti-VEGF therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-025-06993-5","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:23:21Z","timestamp":1760343801000},"page":"91-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced ocular perfusion after intravitreal Aflibercept and faricimab: an exploratory study for Tie2 receptor distribution in ophthalmic capillaries"],"prefix":"10.1007","volume":"264","author":[{"given":"Anna C.","family":"Schuhmayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina A. M.","family":"Karl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Pomberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Eidherr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidar","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kallab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Strohmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Bolz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2218-5897","authenticated-orcid":false,"given":"Anna","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"6993_CR1","doi-asserted-by":"publisher","unstructured":"Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K (2016) Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci. https:\/\/doi.org\/10.1007\/s00018-016-2147-8","DOI":"10.1007\/s00018-016-2147-8"},{"issue":"9","key":"6993_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen P, Eklund L, Alitalo K (2017) Therapeutic targeting of the angiopoietin\u2013TIE pathway. Nat Rev Drug Discov 16(9):635\u2013661. https:\/\/doi.org\/10.1038\/nrd.2016.278","journal-title":"Nat Rev Drug Discov"},{"issue":"6535","key":"6993_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/376070a0","volume":"376","author":"TN Sato","year":"1995","unstructured":"Sato TN et al (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376(6535):70\u201374. https:\/\/doi.org\/10.1038\/376070a0","journal-title":"Nature"},{"key":"6993_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-020-00250-z","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD et al (2020) The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retina Vitreous. https:\/\/doi.org\/10.1186\/s40942-020-00250-z","journal-title":"Int J Retina Vitreous"},{"key":"6993_CR5","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.2147\/OPTH.S476307","volume":"18","author":"T Mizukami","year":"2024","unstructured":"Mizukami T et al (2024) Changes in ocular blood flow after intravitreal injection for diabetic macular edema between aflibercept and faricimab. Clin Ophthalmol 18:2407\u20132416. https:\/\/doi.org\/10.2147\/OPTH.S476307","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"6993_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cyto.2007.09.001","volume":"40","author":"S Peters","year":"2007","unstructured":"Peters S (2007) Angiopoietin modulation of vascular endothelial growth factor: effects on retinal endothelial cell permeability. Cytokine 40(2):144\u2013150. https:\/\/doi.org\/10.1016\/j.cyto.2007.09.001","journal-title":"Cytokine"},{"key":"6993_CR7","doi-asserted-by":"publisher","unstructured":"Liberski S, Wichrowska M, Koci\u0119cki J (2022) Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23169424","DOI":"10.3390\/ijms23169424"},{"key":"6993_CR8","doi-asserted-by":"publisher","unstructured":"Campochiaro PA (2015) Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.06.002","DOI":"10.1016\/j.preteyeres.2015.06.002"},{"issue":"1","key":"6993_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/bjophthalmol-2019-313919","volume":"104","author":"AS Mursch-Edlmayr","year":"2020","unstructured":"Mursch-Edlmayr AS, Luft N, Podkowinski D, Ring M, Schmetterer L, Bolz M (2020) Effects of three intravitreal injections of Aflibercept on the ocular circulation in eyes with age-related maculopathy. Br J Ophthalmol 104(1):53\u201357. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-313919","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"6993_CR10","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1172\/JCI65157","volume":"122","author":"T Kurihara","year":"2012","unstructured":"Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M (2012) Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 122(11):4213\u20134217. https:\/\/doi.org\/10.1172\/JCI65157","journal-title":"J Clin Invest"},{"key":"6993_CR11","doi-asserted-by":"publisher","unstructured":"World Medical Association Declaration of Helsinki, (Nov. 2013) JAMA 310(20):2191. https:\/\/doi.org\/10.1001\/jama.2013.281053","DOI":"10.1001\/jama.2013.281053"},{"issue":"2","key":"6993_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0021-5155(01)00498-1","volume":"46","author":"T Okuno","year":"2002","unstructured":"Okuno T (2002) Effects of caffeine on microcirculation of the human ocular fundus. Jpn J Ophthalmol 46(2):170\u2013176. https:\/\/doi.org\/10.1016\/S0021-5155(01)00498-1","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"6993_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/OPTH.S22093","volume":"5","author":"N Aizawa","year":"2011","unstructured":"Aizawa N et al (2011) Reproducibility of retinal circulation measurements obtained using laser speckle flowgraphy-NAVI in patients with glaucoma. Clin Ophthalmol 5(1):1171\u20131176. https:\/\/doi.org\/10.2147\/OPTH.S22093","journal-title":"Clin Ophthalmol"},{"key":"6993_CR14","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_893_18","author":"F Pichi","year":"2018","unstructured":"Pichi F (2018) Choroidal biomarkers. Indian J Ophthalmol. https:\/\/doi.org\/10.4103\/ijo.IJO_893_18","journal-title":"Indian J Ophthalmol"},{"key":"6993_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47770-9","author":"TE Tan","year":"2019","unstructured":"Tan TE (2019) Global assessment of retinal arteriolar, venular and capillary microcirculations using fundus photographs and optical coherence tomography angiography in diabetic retinopathy. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-47770-9","journal-title":"Sci Rep"},{"key":"6993_CR16","doi-asserted-by":"crossref","unstructured":"Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D\u2019amore PA (2009) An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris, [Online]. Available: www.pnas.org\/cgi\/content\/full\/","DOI":"10.1073\/pnas.0905010106"},{"key":"6993_CR17","doi-asserted-by":"publisher","unstructured":"Inai T (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. https:\/\/doi.org\/10.1016\/S0002-9440(10)63273-7","DOI":"10.1016\/S0002-9440(10)63273-7"},{"issue":"6","key":"6993_CR18","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1161\/01.RES.0000063422.38690.DC","volume":"92","author":"DP Hughes","year":"2003","unstructured":"Hughes DP, Marron MB, Brindle NPJ (2003) The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-\u03baB inhibitor ABIN-2. Circ Res 92(6):630\u2013636. https:\/\/doi.org\/10.1161\/01.RES.0000063422.38690.DC","journal-title":"Circ Res"},{"issue":"4","key":"6993_CR19","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1167\/iovs.18-24522","volume":"60","author":"T Hikichi","year":"2019","unstructured":"Hikichi T, Agarie M (2019) Reduced vessel density of the choriocapillaris during anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 60(4):1088\u20131095. https:\/\/doi.org\/10.1167\/iovs.18-24522","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"6993_CR20","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1111\/aos.14098","volume":"97","author":"AS Mursch-Edlmayr","year":"2019","unstructured":"Mursch-Edlmayr AS, Luft N, Podkowinski D, Ring M, Schmetterer L, Bolz M (2019) Short-term effect on the ocular circulation induced by unilateral intravitreal injection of Aflibercept in age-related maculopathy. Acta Ophthalmol 97(6):e927\u2013e932. https:\/\/doi.org\/10.1111\/aos.14098","journal-title":"Acta Ophthalmol"},{"key":"6993_CR21","doi-asserted-by":"publisher","unstructured":"Pellegrini M et al (2021) Short-term choroidal vascular changes after Aflibercept therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-020-04957-5","DOI":"10.1007\/s00417-020-04957-5"},{"issue":"10","key":"6993_CR22","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.1167\/iovs.10-6646","volume":"52","author":"O Fontaine","year":"2011","unstructured":"Fontaine O, Olivier S, Descovich D, Cordahi G, Vaucher E, Lesk MR (2011) The effect of intravitreal injection of bevacizumab on retinal circulation in patients with neovascular macular degeneration. Invest Ophthalmol Vis Sci 52(10):7400. https:\/\/doi.org\/10.1167\/iovs.10-6646","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6993_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2147\/OPTH.S407249","volume":"17","author":"N Kato","year":"2023","unstructured":"Kato N, Haruta M, Furushima K, Arai R, Matsuo Y, Yoshida S (2023) Decrease in ocular blood flow thirty minutes after intravitreal injections of Brolucizumab and Aflibercept for neovascular age-related macular degeneration. Clin Ophthalmol 17:1187\u20131192. https:\/\/doi.org\/10.2147\/OPTH.S407249","journal-title":"Clin Ophthalmol"},{"key":"6993_CR24","doi-asserted-by":"publisher","unstructured":"Luft N (2016) Ocular blood flow measurements in healthy white subjects using laser speckle flowgraphy. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0168190","DOI":"10.1371\/journal.pone.0168190"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06993-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06993-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:44:02Z","timestamp":1771044242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06993-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6993"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06993-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was not supported by any sponsor or funder.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the (place name of institution and\/or national research committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The the local ethics committee (Ethikkommission des Landes Ober\u00f6sterreichs; registration number 1269\/2023) approved the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No Conflicts of Interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}